Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huanshaodan derivative decoction is a modified Traditional Chinese Medicine (TCM) herbal formulation developed by researchers at Dongfang Hospital of Beijing University of Chinese Medicine specifically for the treatment of multiple system atrophy (MSA). The decoction is based on the classic Huanshaodan formula, which is traditionally used to tonify the kidneys and spleen, nourish essence, and supplement blood. In the context of MSA—a progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia—this derivative version is tailored to address neurodegenerative symptoms by providing neuroprotection and stabilizing autonomic functions. Research suggests that the formula may exert its therapeutic effects by inhibiting the aggregation of alpha-synuclein, reducing neuroinflammation, and mitigating oxidative stress in the central nervous system. It is typically administered as an oral liquid and is used as a complementary therapy to manage the complex symptoms of MSA subtypes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huanshaodan derivative decoction.